C92.2

Clinical Causes: The exact cause of aCML remains unknown; however, it involves genetic mutations that lead to abnormal blood cell production. Environmental factors such as exposure to certain chemicals or radiation may play a role, but evidence is limited. It is not inherited and typically occurs sporadically in adults. Genetic abnormalities in blood cells, apart from BCR/ABL, may contribute to its development.

Key Symptoms: Fatigue and weakness Unintentional weight loss Fever or night sweats Splenomegaly (enlarged spleen) Abdominal discomfort or fullness Easy bruising or bleeding Bone pain or tenderness Frequent infections due to impaired immune function Anemia symptoms such as pallor or shortness of breath

Diagnosis Path: Diagnosing aCML involves a combination of blood tests and bone marrow examination. Key diagnostic steps include: - Complete blood count (CBC) revealing elevated white blood cell count with abnormal cells. - Peripheral blood smear showing atypical granulocytes. - Bone marrow biopsy demonstrating increased granulocytic precursors. - Cytogenetic analysis to rule out the BCR/ABL gene fusion, distinguishing aCML from typical CML. - Molecular testing for other genetic mutations that may be present. These diagnostic methods help differentiate aCML from other myeloproliferative disorders and hematologic malignancies.

Treatment Protocols: Treatment options for aCML are tailored to the patient's condition and may include: - Chemotherapy to control abnormal blood cell growth. - Hypomethylating agents, which may help modify gene expression. - Targeted therapies are limited due to the absence of BCR/ABL fusion. - Supportive care such as blood transfusions and antibiotics to manage symptoms. - Stem cell transplantation could be considered in eligible patients seeking potential cure. Given the rarity of the disease, treatment plans often involve a multidisciplinary team to optimize outcomes.